抗病毒、干扰素药物联合治疗e抗原阳性慢性乙型肝炎疗效分析
|
摘要
目的研究并分析抗病毒、干扰素药物联合治疗e抗原阳性慢性乙型肝炎的临床效果。方法方便选取该院e抗原阳性慢性乙型肝炎患者100例,选取时间为2016年7月—2017年9月,随机分成对照组和观察组,各50例,对照组采取恩替卡韦治疗,观察组在对照组的基础上加用聚乙二醇干扰素α2a注射液,记录并对比两组患者治疗前后的血清HBV-DNA、HBeAg和ALT水平,以及治疗后的临床效果。结果经过治疗后,观察组患者的血清HBV-DNA、HBeAg和ALT水平分别为(2.91±1.01)IgIU/mL、(4.31±1.54)IgIU/mL、(40.35±9.54)U/L,明显低于对照组患者(t=4.36、6.14、5.11,P<0.05)。观察组患者的临床总有效率为94%,明显高于对照组患者的66%,差异有统计学意义(χ~2=12.25,P=0.01)。结论恩替卡韦和聚乙二醇干扰素α2a注射液联合治疗e抗原阳性慢性乙型肝炎,其临床效果较为显著,有效抑制乙肝病毒的复制,改善患者的肝功能。
Objective To study and analyze the clinical effects of antiviral and interferon drugs in the treatment of e antigen-positive chronic hepatitis B. Methods A total of 100 patients with e antigen-positive chronic hepatitis B were enrolled in our hospital. The patients were randomly divided into the control group and the observation group from July 2016 to September 2017. The groups were treated with entecavir. And the control group was supplemented with peginterferon alfa 2 a injection. The serum levels of HBV-DNA, HBeAg and ALT before and after treatment, and the clinical effects after treatment were recorded and compared. Results After treatment, the serum HBV-DNA, HBeAg and ALT levels of the observation group were(2.91±1.01)IgIU/mL,(4.31±1.54)IgIU/mL,(40.35±9.54)U/L, which were significantly lower than those of the control group, the difference was statistically significant(t=4.36, 6.14, 5.11, P=0.01). The total clinical effective rate of the observation group was 94%, which was significantly higher than that of the control group(66%), the difference was statistically significant(χ~2=12.25, P=0.01). Conclusion Entecavir and peginterferon alfa 2 a injection combined with e antigenpositive chronic hepatitis B have clinical effects, which can effectively inhibit the replication of hepatitis B virus and improve liver function.
Objective To study and analyze the clinical effects of antiviral and interferon drugs in the treatment of e antigen-positive chronic hepatitis B. Methods A total of 100 patients with e antigen-positive chronic hepatitis B were enrolled in our hospital. The patients were randomly divided into the control group and the observation group from July 2016 to September 2017. The groups were treated with entecavir. And the control group was supplemented with peginterferon alfa 2 a injection. The serum levels of HBV-DNA, HBeAg and ALT before and after treatment, and the clinical effects after treatment were recorded and compared. Results After treatment, the serum HBV-DNA, HBeAg and ALT levels of the observation group were(2.91±1.01)IgIU/mL,(4.31±1.54)IgIU/mL,(40.35±9.54)U/L, which were significantly lower than those of the control group, the difference was statistically significant(t=4.36, 6.14, 5.11, P=0.01). The total clinical effective rate of the observation group was 94%, which was significantly higher than that of the control group(66%), the difference was statistically significant(χ~2=12.25, P=0.01). Conclusion Entecavir and peginterferon alfa 2 a injection combined with e antigenpositive chronic hepatitis B have clinical effects, which can effectively inhibit the replication of hepatitis B virus and improve liver function.
引文
[1]刘玉柱,闵祥玺.联合应用抗病毒和干扰素药物治疗e抗原阳性慢性乙型肝炎疗效观察[J].医学临床研究,2015,32(10):2004-2006.
[2]郭琴芳,眭静,叶云,等.E抗原阳性慢性乙型肝炎患者干扰素抗病毒药物依从性的影响因素[J].江苏医药,2017,43(2):94-97.
[3]臧玮,田立峰,邱芳,等.拉米夫定耐药e抗原阳性乙型肝炎应用恩替卡韦或阿德福韦酯联合聚乙二醇干扰素α-2a的疗效评价[J].肝脏,2016,21(11):943-945.
[4]鲍旭丽,渠亚超,熊芳,等.聚乙二醇干扰素联合核苷(酸)类似物96周延长疗程治疗e抗原阳性慢性乙型肝炎患者的效果观察[J].中国综合临床,2016,32(8):673-676.
[5]曹振环,柳雅立,马丽娜,等.聚乙二醇干扰素α-2a联合拉米夫定或阿德福韦治疗乙型肝炎e抗原阳性慢性乙型肝炎96周疗效观察[J].中华传染病杂志,2016,34(7):422-424.
[6]李卫,李丽军,李永华,等.回顾性分析聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎患者抗病毒方案调整分析[J].中华医院感染学杂志,2017,27(14):3192-3195.
[7]焦方舟,张海月,刘菲菲,等.长效干扰素与普通干扰素治疗HBeAg阳性慢性乙型肝炎患者疗效的meta分析[J].海南医学,2017,28(8):1354-1360.
[8]滕丹华,张劲,龚天斌,等.干扰素联合拉米夫定治疗e抗原阳性慢性乙型肝炎患者的疗效分析[J].广西医科大学学报,2016,33(6):1039-1041.
[2]郭琴芳,眭静,叶云,等.E抗原阳性慢性乙型肝炎患者干扰素抗病毒药物依从性的影响因素[J].江苏医药,2017,43(2):94-97.
[3]臧玮,田立峰,邱芳,等.拉米夫定耐药e抗原阳性乙型肝炎应用恩替卡韦或阿德福韦酯联合聚乙二醇干扰素α-2a的疗效评价[J].肝脏,2016,21(11):943-945.
[4]鲍旭丽,渠亚超,熊芳,等.聚乙二醇干扰素联合核苷(酸)类似物96周延长疗程治疗e抗原阳性慢性乙型肝炎患者的效果观察[J].中国综合临床,2016,32(8):673-676.
[5]曹振环,柳雅立,马丽娜,等.聚乙二醇干扰素α-2a联合拉米夫定或阿德福韦治疗乙型肝炎e抗原阳性慢性乙型肝炎96周疗效观察[J].中华传染病杂志,2016,34(7):422-424.
[6]李卫,李丽军,李永华,等.回顾性分析聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎患者抗病毒方案调整分析[J].中华医院感染学杂志,2017,27(14):3192-3195.
[7]焦方舟,张海月,刘菲菲,等.长效干扰素与普通干扰素治疗HBeAg阳性慢性乙型肝炎患者疗效的meta分析[J].海南医学,2017,28(8):1354-1360.
[8]滕丹华,张劲,龚天斌,等.干扰素联合拉米夫定治疗e抗原阳性慢性乙型肝炎患者的疗效分析[J].广西医科大学学报,2016,33(6):1039-1041.